Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medivation Gets Hostile After Sanofi's "Misleading" Maneuvers

Executive Summary

The biotech continues to reject offers from the French pharma and lays out the problems it has with the offer to shareholders. Meanwhile, Sanofi has taken its bid hostile and pushes to replace the biotech's board.

Advertisement

Related Content

Medivation Rejects Sanofi's Latest Bid, But Enters Confidential Negotiations
Tesaro Doubles On Super NOVA Data, Lifts PARP Competitors
Sanofi Seeks Medivation Board Overhaul As Buyout Bid Remains Rejected
Sanofi Earnings Emphasize Need For Medivation Buy
Sanofi Goes Public With Hostile Medivation Bid

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC065516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel